UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Leukoreduction to prevent complications of blood transfusion

Author
Arthur J Silvergleid, MD
Section Editor
Steven Kleinman, MD
Deputy Editor
Jennifer S Tirnauer, MD

INTRODUCTION

Leukocytes, while naturally collected along with other cellular elements in a whole blood collection, are considered a contaminant of other cellular blood components (red blood cells and platelets), and have increasingly been recognized as a contributor to, if not the cause of, a number of adverse consequences of blood transfusion:

Immunologically-mediated effects

Infectious disease transmission

Reperfusion injury

Immunologically mediated effects are by far the most common, including:

                     

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Nov 2016. | This topic last updated: Thu Oct 30 00:00:00 GMT+00:00 2014.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
References
Top
  1. Williamson LM. Leucocyte depletion of the blood supply - how will patients benefit? Br J Haematol 2000; 110:256.
  2. BRITTINGHAM TE, CHAPLIN H Jr. Febrile transfusion reactions caused by sensitivity to donor leukocytes and platelets. J Am Med Assoc 1957; 165:819.
  3. Heddle NM, Klama LN, Griffith L, et al. A prospective study to identify the risk factors associated with acute reactions to platelet and red cell transfusions. Transfusion 1993; 33:794.
  4. Stack G, Snyder EL. Cytokine generation in stored platelet concentrates. Transfusion 1994; 34:20.
  5. Sirchia G, Rebulla P, Parravicini A, et al. Leukocyte depletion of red cell units at the bedside by transfusion through a new filter. Transfusion 1987; 27:402.
  6. Mintz PD. Febrile reactions to platelet transfusions. Am J Clin Pathol 1991; 95:609.
  7. Cardigan R, Sutherland J, Garwood M, et al. The effect of leucocyte depletion on the quality of fresh-frozen plasma. Br J Haematol 2001; 114:233.
  8. Yomtovian R, Gernsheimer T, Assmann SF, et al. WBC reduction in RBC concentrates by prestorage filtration: multicenter experience. Transfusion 2001; 41:1030.
  9. Heddle NM, Klama L, Meyer R, et al. A randomized controlled trial comparing plasma removal with white cell reduction to prevent reactions to platelets. Transfusion 1999; 39:231.
  10. Azuma H, Hirayama J, Akino M, et al. Reduction in adverse reactions to platelets by the removal of plasma supernatant and resuspension in a new additive solution (M-sol). Transfusion 2009; 49:214.
  11. Lane TA, Gernsheimer T, Mohandas K, Assmann SF. Signs and symptoms associated with the transfusion of WBC-reduced RBCs and non-WBC-reduced RBCs in patients with anemia and HIV infection: results from the Viral Activation Transfusion Study. Transfusion 2002; 42:265.
  12. Heddle NM. The efficacy of leukodepletion to improve platelet transfusion response: a critical appraisal of clinical studies. Transfus Med Rev 1994; 8:15.
  13. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. The Trial to Reduce Alloimmunization to Platelets Study Group. N Engl J Med 1997; 337:1861.
  14. Seftel MD, Growe GH, Petraszko T, et al. Universal prestorage leukoreduction in Canada decreases platelet alloimmunization and refractoriness. Blood 2004; 103:333.
  15. Blumberg N, Heal JM, Gettings KF. WBC reduction of RBC transfusions is associated with a decreased incidence of RBC alloimmunization. Transfusion 2003; 43:945.
  16. Taylor RW, O'Brien J, Trottier SJ, et al. Red blood cell transfusions and nosocomial infections in critically ill patients. Crit Care Med 2006; 34:2302.
  17. Michalopoulos A, Geroulanos S, Rosmarakis ES, Falagas ME. Frequency, characteristics, and predictors of microbiologically documented nosocomial infections after cardiac surgery. Eur J Cardiothorac Surg 2006; 29:456.
  18. Shorr AF, Jackson WL. Transfusion practice and nosocomial infection: assessing the evidence. Curr Opin Crit Care 2005; 11:468.
  19. Vamvakas EC, Moore SB. Blood transfusion and postoperative septic complications. Transfusion 1994; 34:714.
  20. Murphy P, Heal JM, Blumberg N. Infection or suspected infection after hip replacement surgery with autologous or homologous blood transfusions. Transfusion 1991; 31:212.
  21. Heiss MM, Mempel W, Jauch KW, et al. Beneficial effect of autologous blood transfusion on infectious complications after colorectal cancer surgery. Lancet 1993; 342:1328.
  22. Vamvakas EC, Blajchman MA. Deleterious clinical effects of transfusion-associated immunomodulation: fact or fiction? Blood 2001; 97:1180.
  23. Llewelyn CA, Taylor RS, Todd AA, et al. The effect of universal leukoreduction on postoperative infections and length of hospital stay in elective orthopedic and cardiac surgery. Transfusion 2004; 44:489.
  24. Innerhofer P, Klingler A, Klimmer C, et al. Risk for postoperative infection after transfusion of white blood cell-filtered allogeneic or autologous blood components in orthopedic patients undergoing primary arthroplasty. Transfusion 2005; 45:103.
  25. Jensen LS, Kissmeyer-Nielsen P, Wolff B, Qvist N. Randomised comparison of leucocyte-depleted versus buffy-coat-poor blood transfusion and complications after colorectal surgery. Lancet 1996; 348:841.
  26. Weber WP, Zwahlen M, Reck S, et al. The association of preoperative anemia and perioperative allogeneic blood transfusion with the risk of surgical site infection. Transfusion 2009; 49:1964.
  27. Jensen LS, Andersen AJ, Christiansen PM, et al. Postoperative infection and natural killer cell function following blood transfusion in patients undergoing elective colorectal surgery. Br J Surg 1992; 79:513.
  28. Ottonello L, Ghio M, Contini P, et al. Nonleukoreduced red blood cell transfusion induces a sustained inhibition of neutrophil chemotaxis by stimulating in vivo production of transforming growth factor-beta1 by neutrophils: role of the immunoglobulinlike transcript 1, sFasL, and sHLA-I. Transfusion 2007; 47:1395.
  29. Vamvakas EC, Carven JH. Exposure to allogeneic plasma and risk of postoperative pneumonia and/or wound infection in coronary artery bypass graft surgery. Transfusion 2002; 42:107.
  30. Frietsch T, Karger R, Schöler M, et al. Leukodepletion of autologous whole blood has no impact on perioperative infection rate and length of hospital stay. Transfusion 2008; 48:2133.
  31. Vamvakas EC. WBC-containing allogeneic blood transfusion and mortality: a meta-analysis of randomized controlled trials. Transfusion 2003; 43:963.
  32. Blumberg N. Deleterious clinical effects of transfusion immunomodulation: proven beyond a reasonable doubt. Transfusion 2005; 45:33S.
  33. Blumberg N, Zhao H, Wang H, et al. The intention-to-treat principle in clinical trials and meta-analyses of leukoreduced blood transfusions in surgical patients. Transfusion 2007; 47:573.
  34. Blumberg N, Fine L, Gettings KF, Heal JM. Decreased sepsis related to indwelling venous access devices coincident with implementation of universal leukoreduction of blood transfusions. Transfusion 2005; 45:1632.
  35. Weitz J, D'Angelica M, Gonen M, et al. Interaction of splenectomy and perioperative blood transfusions on prognosis of patients with proximal gastric and gastroesophageal junction cancer. J Clin Oncol 2003; 21:4597.
  36. Hjalgrim H, Edgren G, Rostgaard K, et al. Cancer incidence in blood transfusion recipients. J Natl Cancer Inst 2007; 99:1864.
  37. Chung M, Steinmetz OK, Gordon PH. Perioperative blood transfusion and outcome after resection for colorectal carcinoma. Br J Surg 1993; 80:427.
  38. Amato AC, Pescatori M. Effect of perioperative blood transfusions on recurrence of colorectal cancer: meta-analysis stratified on risk factors. Dis Colon Rectum 1998; 41:570.
  39. Jensen LS, Puho E, Pedersen L, et al. Long-term survival after colorectal surgery associated with buffy-coat-poor and leucocyte-depleted blood transfusion: a follow-up study. Lancet 2005; 365:681.
  40. Amato A, Pescatori M. Perioperative blood transfusions for the recurrence of colorectal cancer. Cochrane Database Syst Rev 2006; :CD005033.
  41. Heiss MM, Mempel W, Delanoff C, et al. Blood transfusion-modulated tumor recurrence: first results of a randomized study of autologous versus allogeneic blood transfusion in colorectal cancer surgery. J Clin Oncol 1994; 12:1859.
  42. Blajchman MA, Bardossy L, Carmen R, et al. Allogeneic blood transfusion-induced enhancement of tumor growth: two animal models showing amelioration by leukodepletion and passive transfer using spleen cells. Blood 1993; 81:1880.
  43. Bordin JO, Bardossy L, Blajchman MA. Growth enhancement of established tumors by allogeneic blood transfusion in experimental animals and its amelioration by leukodepletion: the importance of the timing of the leukodepletion. Blood 1994; 84:344.
  44. Qu L, Xu S, Rowe D, Triulzi D. Efficacy of Epstein-Barr virus removal by leukoreduction of red blood cells. Transfusion 2005; 45:591.
  45. Ronghe MD, Foot AB, Cornish JM, et al. The impact of transfusion of leucodepleted platelet concentrates on cytomegalovirus disease after allogeneic stem cell transplantation. Br J Haematol 2002; 118:1124.
  46. Thiele T, Krüger W, Zimmermann K, et al. Transmission of cytomegalovirus (CMV) infection by leukoreduced blood products not tested for CMV antibodies: a single-center prospective study in high-risk patients undergoing allogeneic hematopoietic stem cell transplantation (CME). Transfusion 2011; 51:2620.
  47. Bowden RA, Slichter SJ, Sayers M, et al. A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood 1995; 86:3598.
  48. Nichols WG, Price TH, Gooley T, et al. Transfusion-transmitted cytomegalovirus infection after receipt of leukoreduced blood products. Blood 2003; 101:4195.
  49. Laupacis A, Brown J, Costello B, et al. Prevention of posttransfusion CMV in the era of universal WBC reduction: a consensus statement. Transfusion 2001; 41:560.
  50. Ljungman P. Risk of cytomegalovirus transmission by blood products to immunocompromised patients and means for reduction. Br J Haematol 2004; 125:107.
  51. Bracey A, Radovancevic R, Radovancevic B, et al. Effect of leukocyte-depleted blood on CMV disease after heart transplant (abstract). XIII Cong ISBT Abstracts 1994; 13.
  52. Busch MP, Lee TH, Heitman J. Allogeneic leukocytes but not therapeutic blood elements induce reactivation and dissemination of latent human immunodeficiency virus type 1 infection: implications for transfusion support of infected patients. Blood 1992; 80:2128.
  53. Asmuth DM, Kalish LA, Laycock ME, et al. Absence of HBV and HCV, HTLV-I and -II, and human herpes virus-8 activation after allogeneic RBC transfusion in patients with advanced HIV-1 infection. Transfusion 2003; 43:451.
  54. Pennington J, Taylor GP, Sutherland J, et al. Persistence of HTLV-I in blood components after leukocyte depletion. Blood 2002; 100:677.
  55. Gong J, Högman CF, Hambraeus A, et al. Transfusion-transmitted Yersinia enterocolitica infection. Protection through buffy coat removal and failure of the bacteria to grow in platelet-rich or platelet-poor plasma. Vox Sang 1993; 65:42.
  56. Pietersz RN, Reesink HW, Pauw W, et al. Prevention of Yersinia enterocolitica growth in red-blood-cell concentrates. Lancet 1992; 340:755.
  57. Cardo LJ, Salata J, Harman R, et al. Leukodepletion filters reduce Leishmania in blood products when used at collection or at the bedside. Transfusion 2006; 46:896.
  58. Riera C, Fisa R, López-Chejade P, et al. Asymptomatic infection by Leishmania infantum in blood donors from the Balearic Islands (Spain). Transfusion 2008; 48:1383.
  59. Pearl JM, Drinkwater DC Jr, Laks H, et al. Leukocyte-depleted reperfusion of transplanted human hearts prevents ultrastructural evidence of reperfusion injury. J Surg Res 1992; 52:298.
  60. van de Watering LM, Hermans J, Houbiers JG, et al. Beneficial effects of leukocyte depletion of transfused blood on postoperative complications in patients undergoing cardiac surgery: a randomized clinical trial. Circulation 1998; 97:562.
  61. Wallis JP, Chapman CE, Orr KE, et al. Effect of WBC reduction of transfused RBCs on postoperative infection rates in cardiac surgery. Transfusion 2002; 42:1127.
  62. Bilgin YM, van de Watering LM, Eijsman L, et al. Double-blind, randomized controlled trial on the effect of leukocyte-depleted erythrocyte transfusions in cardiac valve surgery. Circulation 2004; 109:2755.
  63. Jensen LS, Grunnet N, Hanberg-Sørensen F, Jørgensen J. Cost-effectiveness of blood transfusion and white cell reduction in elective colorectal surgery. Transfusion 1995; 35:719.
  64. Belloni M, Alghisi A, Bettini C, et al. Hypotensive reactions associated with white cell-reduced apheresis platelet concentrates in patients not receiving ACE Inhibitors. Transfusion 1998; 38:412.
  65. www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm079813.htm (Accessed on June 23, 2011).
  66. Recommendations and licensure requirements for leukocyte-reduced blood products; May 29, 1996. Division of Blood Applications, Food and Drug Administration, Center for Biologics Evaluation and Research. Available at: www.fda.gov/cber/bldmem/mem52996.txt (Accessed on March 08, 2005).
  67. http://www.fda.gov/biologicsbloodvaccines/guidancecomplianceregulatoryinformation/guidances/blood/ucm320636.htm (Accessed on March 04, 2014).
  68. Krailadsiri P, Gilcher R, Seghatchian J. Leukoreduction of sickle cell trait blood: an unresolved issue. Transfus Apher Sci 2001; 24:223.
  69. Jacob EK, Emery RL, Orrock JM, et al. Filter failures with sickling hemoglobin. Transfusion 2009; 49:1535.
  70. Stroncek DF, Byrne KM, Noguchi CT, et al. Increasing hemoglobin oxygen saturation levels in sickle trait donor whole blood prevents hemoglobin S polymerization and allows effective white blood cell reduction by filtration. Transfusion 2004; 44:1293.
  71. Beard MJ, Cardigan R, Seghatchian J, et al. Variables determining blockage of WBC-depleting filters by Hb sickle cell trait donations. Transfusion 2004; 44:422.
  72. Bryant BJ, Bianchi M, Wesley RA, et al. Leukoreduction filtration of whole-blood units from sickle trait donors: effects of a metered citrate anticoagulant system. Transfusion 2007; 47:2233.
  73. Alonso-Echanove J, Sippy BD, Chin AE, et al. Nationwide outbreak of red eye syndrome associated with transfusion of leukocyte-reduced red blood cell units. Infect Control Hosp Epidemiol 2006; 27:1146.
  74. Oba T, Tsuji K, Nakamura A, et al. Migration of acetylated hemicellulose from capillary hemodialyzer to blood, causing scleritis and/or iritis. Artif Organs 1984; 8:429.
  75. Hutter JC, Kuehnert MJ, Wallis RR, et al. Acute onset of decreased vision and hearing traced to hemodialysis treatment with aged dialyzers. JAMA 2000; 283:2128.
  76. Averbukh Z, Modai D, Sandbank J, et al. Red eye syndrome: clinical and experimental experience in a new aspect of diffuse eosinophilic infiltration? Artif Organs 2001; 25:437.
  77. Goodnough LT. The case against universal WBC reduction (and for the practice of evidence-based medicine). Transfusion 2000; 40:1522.
  78. Vamvakas EC, Blajchman MA. Universal WBC reduction: the case for and against. Transfusion 2001; 41:691.
  79. Uhlmann EJ, Isgriggs E, Wallhermfechtel M, Goodnough LT. Prestorage universal WBC reduction of RBC units does not affect the incidence of transfusion reactions. Transfusion 2001; 41:997.
  80. Dzik WH, Anderson JK, O'Neill EM, et al. A prospective, randomized clinical trial of universal WBC reduction. Transfusion 2002; 42:1114.
  81. Ratko TA, Cummings JP, Oberman HA, et al. Evidence-based recommendations for the use of WBC-reduced cellular blood components. Transfusion 2001; 41:1310.
  82. Preiksaitis JK, Sandhu J, Strautman M. The risk of transfusion-acquired CMV infection in seronegative solid-organ transplant recipients receiving non-WBC-reduced blood components not screened for CMV antibody (1984 to 1996): experience at a single Canadian center. Transfusion 2002; 42:396.
  83. Vamvakas EC. Platelet transfusion and adverse outcomes. Lancet 2004; 364:1736.
  84. Blumberg N, Heal JM, Gettings KF, et al. An association between decreased cardiopulmonary complications (transfusion-related acute lung injury and transfusion-associated circulatory overload) and implementation of universal leukoreduction of blood transfusions. Transfusion 2010; 50:2738.
  85. Schiffer CA, Anderson KC, Bennett CL, et al. Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001; 19:1519.
  86. Vamvakas EC, Blajchman MA. Blood still kills: six strategies to further reduce allogeneic blood transfusion-related mortality. Transfus Med Rev 2010; 24:77.
  87. Blajchman MA. Transfusion-associated immunomodulation and universal white cell reduction: are we putting the cart before the horse? Transfusion 1999; 39:665.